JaLCDOI 10.18926/AMO/30737
FullText URL fulltext.pdf
Author Suzaki, Noriyuki| Hiraki, Akio| Takigawa, Nagio| Ueoka, Hiroshi| Tanimoto, Yasushi| Kozuki, Toshiyuki| Tabata, Masahiro| Kanehiro, Arihiko| Kiura, Katsuyuki| Tanimoto, Mitsune|
Abstract A 71-year-old Japanese man with adenocarcinoma of the lung developed interstitial pneumonia after treatment with paclitaxel. The patient had acute chills and fever on the fourth day after the second exposure to paclitaxel, rapidly got worse despite empiric therapies, and developed prolonged respiratory failure requiring mechanical ventilation. Four months later, he died of respiratory failure due to progression of both interstitial pneumonia and lung cancer. This is the first case developing fatal paclitaxel-induced pulmonary toxicity to date. Interstitial pneumonia should be considered one of the possible life-threatening complications during treatment with paclitaxel.
Keywords paclitaxel adverse effect lung cancer interstitial pneumonia
Amo Type Article
Published Date 2006-10
Publication Title Acta Medica Okayama
Volume volume60
Issue issue5
Publisher Okayama University Medical School
Start Page 295
End Page 298
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 17072376
Web of Science KeyUT 000241509000006
JaLCDOI 10.18926/AMO/48564
FullText URL 66_3_245.pdf
Author Okada, Toshiaki| Takigawa, Nagio| Kishino, Daizo| Katayama, Hideki| Kuyama, Shouichi| Sato, Ken| Mimoto, Junko| Ueoka, Hiroshi| Tanimoto, Mitsune| Kiura, Katsuyuki|
Abstract Cisplatin is used to treat lung cancer;however, it is also a known carcinogen. Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced experimental tumors. We investigated the effect of a COX-2 inhibitor, celecoxib, on cisplatin-induced lung tumors. One hundred twenty 4-week-old A/J mice were divided into 6 groups:group 1, no treatment;group 2, low-dose celecoxib (150mg/kg);group 3, high-dose celecoxib (1,500mg/kg);group 4, cisplatin alone;group 5, cisplatin plus low-dose celecoxib;and group 6, cisplatin plus high-dose celecoxib. Mice in groups 4-6 were administered cisplatin (1.62mg/kg, i.p.) once a week for 10 weeks between 7 and 16 weeks of age. All mice were sacrificed at week 30. Tumor incidence was 15.8% in group 1, 25% in group 2, 26.3% in group 3, 60% in group 4, 50% in group 5, and 50% in group 6. Tumor multiplicity was 0.2, 0.3, 0.3, 1.3, 1.0, and 0.6 in groups 1-6, respectively. Tumor multiplicity in the cisplatin-treated mice was reduced by celecoxib treatment in a dose-dependent manner (p<0.05, group 4 vs. group 6). Celecoxib significantly reduced COX-2 expression in cisplatin-induced tumors (p<0.01, group 4 vs. group 6).
Keywords cisplatin non-small cell lung cancer celecoxib cyclooxygenase-2 chemoprevention
Amo Type Original Article
Published Date 2012-06
Publication Title Acta Medica Okayama
Volume volume66
Issue issue3
Publisher Okayama University Medical School
Start Page 245
End Page 251
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2012 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 22729105
Web of Science KeyUT 000305669700008
FullText URL fulltext.pdf
Author Sugiura, Hiroyuki| Nishimori, Hisakazu| Nishii, Kazuya| Toji, Tomohiro| Fujii, Keiko| Fujii, Nobuharu| Matsuoka, Ken-ichi| Nakata, Koh| Kiura, Katsuyuki| Maeda, Yoshinobu|
Keywords pulmonary alveolar proteinosis primary myelofibrosis autopsy ruxolitinib
Published Date 2020-08-15
Publication Title Internal Medicine
Volume volume59
Issue issue16
Start Page 2023
End Page 2028
ISSN 0918-2918
NCID AA10827774
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2020 by The Japanese Society of Internal Medicine
File Version publisher
PubMed ID 32448830
DOI 10.2169/internalmedicine.4082-19
Web of Science KeyUT 000563078400014
Related Url isVersionOf https://doi.org/10.2169/internalmedicine.4082-19
FullText URL fulltext.pdf
Author Katsui, Kuniaki| Ogata, Takeshi| Sugiyama, Soichi| Yoshio, Kotaro| Kuroda, Masahiro| Hiraki, Takao| Kiura, Katsuyuki| Maeda, Yoshinobu| Toyooka, Shinichi| Kanazawa, Susumu|
Published Date 2021-06-04
Publication Title scientific reports
Volume volume11
Issue issue1
Publisher Nature Research
Start Page 11882
ISSN 2045-2322
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © The Author(s) 2021
File Version publisher
PubMed ID 34088965
DOI 10.1038/s41598-021-91449-z
Web of Science KeyUT 000678611200010
Related Url isVersionOf https://doi.org/10.1038/s41598-021-91449-z
JaLCDOI 10.18926/AMO/30751
FullText URL fulltext.pdf
Author Kitajima, Takuji| Nishii, Kenji| Ueoka, Hiroshi| Shibayama, Takuo| Gemba, Kenichi| Kodani, Tsuyoshi| Kiura, Katsuyuki| Tabata, Masahiro| Hotta, Katsuyuki| Tanimoto, Mitsune| Sobue, Tomotaka|
Abstract <p>To evaluate recent improvements in lung cancer screening, we compared the results of recently conducted lung cancer screening with those of a previous screening. This study compared the survival of lung cancer patients detected by lung cancer screening conducted between 1976 and 1984 (early period) with that conducted between 1989 and 1997 (late period). Two hundred seventy-six patients with lung cancer were detected in the early period and 541 patients with lung cancer were detected in the late period. The median survival time (late : 49.8 vs. early : 27.8 months) and the 5-year survival rate (late : 47.8 vs. early : 34.8%) of the patients with lung cancer detected in the late period were significantly better than those in the early period (p = 0.0054). Among patients undergoing resection, the proportion of pathological stage I patients in the late period was significantly higher than that in the early period (late : 60.8 vs. early : 54.9%, p = 0.005). Multivariate analysis showed that the screening time period was a significant prognostic factor (hazard ratio = 0.685, 95% confidence interval : 0.563-0.832, p = 0.0002). These results were consistent with the findings of case-control studies of lung cancer screening programs in the late period recently conducted in Japan, which also showed a greater efficacy for screening than for previous case-control studies in the early period.</p>
Keywords lung cancer screening survival lung cancer mortality
Amo Type Article
Published Date 2006-06
Publication Title Acta Medica Okayama
Volume volume60
Issue issue3
Publisher Okayama University Medical School
Start Page 173
End Page 179
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 16838046
Web of Science KeyUT 000238503600005
JaLCDOI 10.18926/AMO/60802
FullText URL 74_5_423.pdf
Author Hirabae, Atsuko| Ichihara, Eiki| Sunami, Ryota| Ota, Moeko| Iwamoto, Yoshitaka| Maeda, Yoshinobu| Kiura, Katsuyuki|
Abstract We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks.
Keywords lung cancer immune checkpoint inhibitors pembrolizumab hyperprogression
Amo Type Case Report
Published Date 2020-10
Publication Title Acta Medica Okayama
Volume volume74
Issue issue5
Publisher Okayama University Medical School
Start Page 423
End Page 425
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2020 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 33106698
Web of Science KeyUT 000581970100007
NAID 120006892928
FullText URL J_Thorac_Oncol_201907017.pdf
Author Makimoto, Go| Ohashi, Kadoaki| Tomida, Shuta| Nishii, Kazuya| Matsubara, Takehiro| Kayatani, Hiroe| Higo, Hisao| Ninomiya, Kiichiro| Sato, Akiko| Watanabe, Hiromi| Kano, Hirohisa| Ninomiya, Takashi| Kubo, Toshio| Rai, Kammei| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Toyooka, Shinichi| Takata, Minoru| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords ALK G1202R Alectinib Amphiregulin MET NSCLC
Published Date 2019-07-30
Publication Title Journal of Thoracic Oncology
Volume volume14
Issue issue11
Publisher Elsevier
Start Page 2009
End Page 2018
ISSN 15560864
NCID AA12058455
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
File Version author
PubMed ID 31374369
DOI 10.1016/j.jtho.2019.07.017
Web of Science KeyUT 000492678300025
Related Url isVersionOf https://doi.org/10.1016/j.jtho.2019.07.017
FullText URL fulltext.pdf
Author Katsui, Kuniaki| Ogata, Takeshi| Watanabe, Kenta| Katayama, Norihisa| Kuroda, Masahiro| Kiura, Katsuyuki| Hiraki, Takao| Maeda, Yoshinobu| Toyooka, Shinichi| Kanazawa, Susumu|
Keywords cisplatin docetaxel dose-volume histogram non-small cell lung cancer PACIFIC trial radiation pneumonitis
Published Date 2020-05-04
Publication Title Cancer Medicine
Publisher Wiley
ISSN 2045-7634
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2020 The Authors.
File Version publisher
PubMed ID 32364685
DOI 10.1002/cam4.3093
Web of Science KeyUT 000530411600001
Related Url isVersionOf https://doi.org/10.1002/cam4.3093
FullText URL fulltext.pdf
Author Sugimoto, Seiichiro| Soh, Junichi| Suzawa, Ken| Miyoshi, Kentaroh| Otani, Shinji| Yamamoto, Hiromasa| Okazaki, Mikio| Yamane, Masaomi| Oto, Takahiro| Kanazawa, Susumu| Kiura, Katsuyuki| Toyooka, Shinichi|
Keywords Lung cancer Aspergillosis Surgery Radiation Chemotherapy
Note This is a post-peer-review, pre-copyedit version of an article published in Surgery Today. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00595-020-01960-5.|
Published Date 2020-01-21
Publication Title Surgery Today
Volume volume50
Issue issue8
Publisher Springer
Start Page 863
End Page 871
ISSN 0941-1291
NCID AA10824685
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
File Version author
PubMed ID 31965262
DOI 10.1007/s00595-020-01960-5
Web of Science KeyUT 000550244700010
Related Url isVersionOf https://doi.org/10.1007/s00595-020-01960-5
JaLCDOI 10.18926/AMO/55446
FullText URL 71_5_453.pdf
Author Taniguchi, Akihiko| Miyahara, Nobuaki| Oda, Naohiro| Morichika, Daisuke| Ichihara, Eiki| Oze, Isao| Tanimoto, Yasushi| Ichikawa, Hirohisa| Fujii, Utako| Tanimoto, Mitsune| Kanehiro, Arihiko| Kiura, Katsuyuki|
Abstract Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart failure, the effects of β-blockers on COPD patients without heart failure have not been established. Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication. The primary endpoint is the rate of mild-to-severe COPD exacerbation. The results of this study will clarify whether bisoprolol can prevent exacerbation in COPD patients without heart failure.
Keywords chronic obstructive pulmonary disease β-blocker bisoprolol exacerbation heart failure
Amo Type Clinical Study Protocol
Published Date 2017-10
Publication Title Acta Medica Okayama
Volume volume71
Issue issue5
Publisher Okayama University Medical School
Start Page 453
End Page 457
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2017 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 29042706
Author Shien, Kazuhiko| Toyooka, Shinichi| Ichimura, Kouichi| Soh, Junichi| Furukawa, Masashi| Maki, Yuho| Muraoka, Takayuki| Tanaka, Norimitsu| Ueno, Tsuyoshi| Asano, Hiroaki| Tsukuda, Kazunori| Yamane, Masaomi| Oto, Takahiro| Kiura, Katsuyuki| Miyoshi, Shinichiro|
Published Date 2012-07
Publication Title Lung Cancer
Volume volume77
Issue issue1
Content Type Journal Article
JaLCDOI 10.18926/AMO/31310
FullText URL fulltext.pdf
Author Tamura, Makoto| Ueoka, Hiroshi| Kiura, Katsuyuki| Tabata, Masahiro| Shibayama, Takuo| Miyatake, Kazuyo| Genba, Kenichi| Hiraki, Shunkichi| harada, Mine|
Abstract <p>In order to elucidate factors influencing the prognosis of small-cell lung cancer (SCLC), we reviewed the records of 253 patients with SCLC and evaluated 20 pretreatment prognostic factors by univariate analysis and Cox's multiple regression analysis. Recursive partitioning and amalgamation (RPA) was employed to identify subgroups with similar survival rates. Cox's multiple regression analysis identified five significant factors: extent of disease, number of metastatic sites, serum albumin, serum lactate dehydrogenase, and presence of weight loss. Among these, extent of disease was the most influential factor. RPA analysis revealed three subgroups predicting significantly different prognoses. The median survival time and 3-year survival rate were 18.4 months and 20.6%, respectively for the good-risk group (limited disease without weight loss), 13.5 months and 9.1%, respectively for the intermediate-risk group (limited disease with weight loss or extensive disease with less than two metastatic sites), and 9.2 months and 0%, respectively for the poor-risk group (extensive disease with two or more metastatic sites). These results will be useful for development of new staging system or subsequent stratification for randomized trials.</p>
Keywords prognostic factors Cox's multiple regression analysis recursive partitioning and amalgamayion method small-sell lung canser
Amo Type Article
Published Date 1998-04
Publication Title Acta Medica Okayama
Volume volume52
Issue issue2
Publisher Okayama University Medical School
Start Page 105
End Page 111
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 9588226
Web of Science KeyUT 000073363000006
JaLCDOI 10.18926/AMO/53671
FullText URL 69_5_261.pdf
Author Nojima, Daisuke| Fujimoto, Nobukazu| Kato, Katsuya| Fuchimoto, Yasuko| Kiura, Katsuyuki| Kishimoto, Takumi| Tanimoto, Mitsune|
Abstract We investigated the clinical features of asbestos-induced diffuse pleural thickening (DPT) with severe respiratory compromise. We conducted a retrospective study of consecutive subjects with asbestos-induced DPT. Medical data such as initial symptoms, radiological findings, respiratory function test results, and clinical course were collected and analyzed. There were 24 patients between 2003 and 2012. All were men, and the median age at the development of DPT was 74 years. The top occupational category associated with asbestos exposure was dockyard workers. The median duration of asbestos exposure was 35.0 years, and the median latency from first exposure to the onset of DPT was 49.0 years. There were no significant differences in respiratory function test results between the higher and lower Brinkman index groups or between unilateral and bilateral DPT. Thirteen patients had a history of benign asbestos pleural effusion (BAPE), and the median duration from pleural fluid accumulation to DPT with severe respiratory compromise was 28.4 months. DPT with severe respiratory compromise can develop after a long latency following occupational asbestos exposure and a history of BAPE.
Keywords asbestos pleural thickening MRC dyspnea scale respiratory function test costophrenic angle
Amo Type Original Article
Published Date 2015-10
Publication Title Acta Medica Okayama
Volume volume69
Issue issue5
Publisher Okayama University Medical School
Start Page 261
End Page 266
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26490022
Web of Science KeyUT 000365519600001
JaLCDOI 10.18926/AMO/32200
FullText URL fulltext.pdf
Author Ohnoshi, Taisuke| Hiraki, Shunkichi| Ueda, Nobuo| Fujii, Masafumi| Machida, Ken-ichi| Ueoka, Hiroshi| Kawahara, Shin| Kozuka, Akira| Kiura, Katsuyuki| Moritaka, Tomonori| Kodani, Tsuyoshi| Kamei, Haruhito| Kimura, Ikuro|
Abstract <p>Twenty-seven previously untreated patients with unresectable non-small cell lung cancer were treated with a 3-drug combination of ifosfamide, cisplatin, and vindesine as a phase II study. Patients received ifosfamide, 1.3g/m2, on days 1 to 5; cisplatin, 20mg/m2, on days 1 to 5; and vindesine, 3mg/m2, on days 1 and 8; with a sufficient parenteral hydration. Courses were repeated every 4 weeks. Twenty males and seven females with a median age of 61 years were treated and fully evaluated. Five patients had stage IIIA, seven had stage IIIB, and 15 had stage IV disease. One patient with adenocarcinoma achieved a complete response and 16 achieved a partial response, for an overall response rate of 63% (95% confidence limit: 45% to 81%). The median duration of response was 34 weeks (range: 9 to 52 weeks). The median survival time was 58 weeks for patients with IIIA/B disease, and 33 weeks for those with IV disease. The major toxicity was myelosuppression, however, it was generally well-tolerated. These results indicate that the 3-drug combination is active against non-small cell lung cancer and warrants further clinical trials.</p>
Keywords non-small cell lung cancer ifosfamide cisplatin vindesine
Amo Type Article
Published Date 1991-10
Publication Title Acta Medica Okayama
Volume volume45
Issue issue5
Publisher Okayama University Medical School
Start Page 357
End Page 361
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 1661559
Web of Science KeyUT A1991GN53800010
FullText URL fulltext.pdf
Author Nishii, Kazuya| Inoue, Masaaki| Obata, Hideto| Ueda, Yutaka| Kozuki, Toshiyuki| Yamasaki, Masahiro| Moritaka, Tomonori| Awaya, Yoshikazu| Sugimoto, Keisuke| Gemba, Kenichi| Kuyama, Shoichi| Ichikawa, Hirohisa| Shibayama, Takuo| Kubota, Tetsuya| Kodani, Masahiro| Kishino, Daizo| Fujimoto, Nobukazu| Ishikawa, Nobuhisa| Tsubata, Yukari| Ishii, Tomoya| Fujitaka, Kazunori| Hotta, Katsuyuki| Kiura, Katsuyuki|
Keywords Database observational study real world data surveillance treatment
Published Date 2021-01-12
Publication Title Thoracic Cancer
Volume volume12
Issue issue5
Publisher Wiley
Start Page 725
End Page 731
ISSN 1759-7706
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2020 The Authors.
File Version publisher
PubMed ID 33434415
DOI 10.1111/1759-7714.13789
Web of Science KeyUT 000606961500001
Related Url isVersionOf https://doi.org/10.1111/1759-7714.13789
FullText URL fulltext.pdf
Author Senoo, Satoru| Miyahara, Nobuaki| Taniguchi, Akihiko| Oda, Naohiro| Itano, Junko| Higo, Hisao| Hara, Naofumi| Watanabe, Hiromi| Kano, Hirohisa| Suwaki, Toshimitsu| Fuchimoto, Yasuko| Kajimoto, Kazuhiro| Ichikawa, Hirohisa| Kudo, Kenichiro| Shibayama, Takuo| Tanimoto, Yasushi| Kuyama, Shoichi| Kanehiro, Arihiko| Maeda, Yoshinobu| Kiura, Katsuyuki| Okayama Respiratory Disease Study Group (ORDSG)|
Published Date 2020-08-27
Publication Title PLoS ONE
Volume volume15
Issue issue8
Publisher Public Library of Science
Start Page e0236935
ISSN 1932-6203
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2020 Senoo et al.
File Version publisher
PubMed ID 32853277
DOI 10.1371/journal.pone.0236935
Web of Science KeyUT 000566948800009
Related Url isVersionOf https://doi.org/10.1371/journal.pone.0236935
JaLCDOI 10.18926/AMO/31591
FullText URL fulltext.pdf
Author Ohnoshi, Taisuke| Hiraki, Shunkichi| Fujii, Masafumi| Ueoka, Hiroshi| Yonei, Toshiro| Tamura, Makoto| Moritaka, Tomonori| Mima, Yuchi| Horiguchi, Takashi| Kiura, Katsuyuki| Kamei, Haruhito| Kodani, Tsuyoshi| Hiraki, Yoshio| Kimura, Ikuro|
Abstract <p>We evaluated the long-term outcome of 148 patients with small cell lung cancer (SCLC) who had been entered into clinical trials of chemotherapy with or without thoracic and prophylactic cranial irradiation (PCI) between 1981 and 1987. Eighteen patients (12%) survived for 2 or more years. With a minimum follow-up of 4.5 years, 10 of the 18 patients who remained disease-free at 2 years are currently alive and free of SCLC. Seven of these 10 patients currently function as they did before diagnosis. However, three suffer from central nervous system changes of varying degrees in severity which appeared 2-3 years after PCI. Eight of the 18 patients who were disease-free at 2 years have died. Two died of isolated relapse in the brain at 3.6 and 4.2 years after initiation of chemotherapy. Five died of other malignancies while continuing their complete response to SCLC; two of non-small cell lung cancer, two of acute myelogenous leukemia, and one of hepatocellular carcinoma. Another patient died of an unrelated disease without any evidence of SCLC. A small but substantial proportion of patients who underwent intensive treatment will achieve long-term survival; however, these patients remain at higher risk for second cancers and late toxicities. Therefore, attention must be directed to defining the safest way to employ such treatment in the management of SCLC.</p>
Keywords small cell lung cancer long-term survivors late relapse toxicities complications
Amo Type Article
Published Date 1993-06
Publication Title Acta Medica Okayama
Volume volume47
Issue issue3
Publisher Okayama University Medical School
Start Page 209
End Page 214
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 8397470
Web of Science KeyUT A1993LL12400010
FullText URL fulltext.pdf
Author Okawa, Sachi| Rai, Kammei| Fujii, Nobuharu| Gion, Yuka| Ninomiya, Kiichiro| Kato, Yuka| Taniguchi, Akihiko| Kubo, Toshio| Ichihara, Eiki| Ohashi, Kadoaki| Miyahara, Nobuaki| Hotta, Katsuyuki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords EGFR IgG4-related disease marginal zone lymphoma osimertinib
Published Date 2021-09-01
Publication Title Internal Medicine
Volume volume60
Issue issue17
Publisher The Japanese Society of Internal Medicine
Start Page 2831
End Page 2837
ISSN 0918-2918
NCID AA10827774
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2021 The Japanese Society of Internal Medicine
File Version publisher
PubMed ID 33775999
DOI 10.2169/internalmedicine.6470-20
Web of Science KeyUT 000695856000020
Related Url isVersionOf https://doi.org/10.2169/internalmedicine.6470-20
FullText URL fulltext.pdf
Author Ichihara, Eiki| Miyahara, Nobuaki| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords lung cancer interstitial pneumonia
Published Date 2020-01-15
Publication Title Internal Medicine
Volume volume59
Issue issue2
Publisher 日本内科学会
Start Page 163
End Page 167
ISSN 0918-2918
NCID AA10827774
Content Type Journal Article
language 英語
Copyright Holders © 2020 by The Japanese Society of Internal Medicine
File Version publisher
PubMed ID 31534086
NAID 130007785095
DOI 10.2169/internalmedicine.3481-19
Web of Science KeyUT 000507577600002
Related Url isVersionOf https://doi.org/10.2169/internalmedicine.3481-19
JaLCDOI 10.18926/AMO/31553
FullText URL fulltext.pdf
Author Tabata, Masahiro| Ohnoshi, Taisuke| Ueoka, Hiroshi| Kiura, Katsuyuki| Kimura, Ikuro|
Abstract <p>We report a preliminary study to determine whether MDR1 gene expression level in small cell lung cancer (SCLC) tumors is a useful predictor of tumor response to chemotherapy and patient survival in association with myc amplification in the tumor. We analyzed 18 patients with SCLC receiving adriamycin and etoposide combination chemotherapy between August 1989 and November 1991; 16 males and 2 females, median age of 68 years, and 7 with limited disease and 11 with extensive disease. MDR1 mRNA expression level and myc family gene amplification were simultaneously determined by polymerase chain reaction using transbronchial biopsy specimens which were obtained at diagnosis. Patients with tumors expressing low MDR1 mRNA responded more favorably to chemotherapy than those with tumors expressing high MDRI mRNA, however, the difference in tumor response was statistically not significant (84.6% versus 40%). The overall survival was significantly shorter in the latter than in the former (7.2 months versus 11.7 months; p = 0.023). The survival of the 4 patients with tumor showing myc family gene amplification was almost identical to that of patients with tumors showing no amplification of the gene (8.2 months versus 8.8 months; p = 0.73). Multivariate Cox's regression analysis supports the notion that MDR1 may be a useful independent prognostic factor.</p>
Keywords small cell lung cancer MDR1 mRNA expression myc gene amplification prognostic factor
Amo Type Article
Published Date 1993-08
Publication Title Acta Medica Okayama
Volume volume47
Issue issue4
Publisher Okayama University Medical School
Start Page 243
End Page 248
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 8213218
Web of Science KeyUT A1993LV73800004